Scott Andrew Smith
CEO & DirectorMr. Scott Andrew Smith is Director at Viatris Inc. since December 29, 2022 and serves as its Chief Executive Officer since April 1, 2023. He serves as President of Global Inflammation and Immunology at Celgene Limited since August 1, 2014. Mr. Smith is the Founder of GreenRiver BioPharma LLC. He serves as Chairman of the Board of Triumvira Immunologics USA, Inc. Mr. Smith had been an Independence of Director of Titan Pharmaceuticals, Inc. since January 4, 2017 until 2020. He has been Independent Director of Spring Bank Pharmaceuticals Inc. since August 15, 2018 and Chairman of the Board since January 1, 2019. He was a Director of Refuge Biotechnologies Inc. from 2018 to 2022. He was a Director of F-star Therapeutics, Inc. from 2018 to 2020. He was Director of Triumvira Immunologics, Inc. since June 2018 until 2023 and served as its Chairman of the Board until 2023. He served as President of BioAtla, Inc. since September 10, 2018 until February 27, 2023 and had been its Director since July 2020 until July 16, 2026. He served as the President and Chief Operating Officer of Celgene Corporation from April 1, 2017 to April 3, 2018. He was an Independent Director of Apexigen Inc from September 4, 2019 to 2023. Mr. Smith served as the President of Global Inflammation and Immunology at Celgene Corporation and Celgene Limited since August 1, 2014 until April 1, 2017. Mr. Smith is responsible for the inflammation and immunology portfolio, including all global commercial, clinical development, regulatory, medical affairs and finance activities. He served as the Head of Inflammation & Immunology and Vice President at Celgene Corporation since May 2010 and its Senior Vice President. He joined Celgene in 2008 as Vice President of Global Marketing Inflammation and Immunology. Mr. Smith's prior experience at Pharmacia (acquired by Pfizer) and at Biovail included global responsibility for sales and marketing, creating and executing commercial and business development strategies and contributing to regulatory and clinical development strategies. Prior to joining Celgene in 2008, Mr. Smith was a Vice President & General Manager and Head of strategic marketing and business analysis at Biovail Pharmaceuticals, Inc. From 2005 to 2008, he was with Biovail holding positions of General Manager of Biovail US, Biovail Canada and Global Commercial Head. As Global Commercial Head for Biovail, he was responsible for global revenue generation, global commercial strategies, business development strategy and input into global regulatory and clinical development strategies. From 2003 to 2005, he served as Vice President and Head US Sales for Biovail. Prior to working for Biovail, he was with Pharmacia (acquired by Pfizer) and Upjohn. Prior to Biovail, Mr. Smith was with Pharmacia/Upjohn, where he held various positions including Vice President U. S. Sales, Vice President Marketing Europe based in Paris, Vice President and Commercial Lead for Canada based in Toronto and Commercial and Regulatory Head for South East Asia based in Hong Kong. Mr. Smith has extensive experience in product development and commercialization as well as business development. Mr. Smith holds a BSc in Chemistry and Biology and an HBSc in Pharmacology and Toxicology from the University of Western Ontario and received his MS in International Management from the American Graduate School of International Management. (Thunderbird).
Positions
- Company NameViatris Inc.Stock CodeVTRSPositionCEO & DirectorColleagues
- MEMelina E. HigginsIndependent Non-Executive Chairman
- AEAndrew EnriettiChief Administrative & Transformation Officer
- CMCorinne M. Le GoffChief Commercial Officer
- PBPaul B. CampbellInterim CFO, Chief Accounting Officer & Corporate Controller
- RVRamkumar V. RayapureddyChief Information Officer
- MWMark W. ParrishIndependent Vice Chairman & Lead Independent Director
- JLJoEllen Lyons DillonIndependent Non-Executive Director
- RARichard A. MarkIndependent Director
